Published in final edited form as:

J Health Care Poor Underserved. 2003 November ; 14(4): 478–488.

SOCIAL, PROGNOSTIC, AND THERAPEUTIC FACTORS ASSOCIATED WITH CANCER SURVIVAL: A POPULATION- BASED STUDY IN METROPOLITAN DETROIT, MICHIGAN

Kevin M. Gorey, PhD, MSW [Professor],

School of Social Work, University of Windsor, Windsor, Canada

Eric J. Holowaty, MD, FRCPC, MSc [Director],

Cancer Surveillance Unit, Division of Preventive Oncology, Cancer Care Ontario, Toronto, Canada

Ethan Laukkanen, MD, FRCPC [Director], and

Research, Education and Development, Windsor Regional Hospital, Windsor, Canada

Isaac N. Luginaah, PhD [Assistant Professor]

Department of Sociology and Anthropology, University of Windsor, Windsor, Canada

Previously, we studied the effect of socioeconomic status (SES) on cancer survival among adults of Toronto, Ontario and Detroit, Michigan.¹ Detroiters' survival was significantly worse among people from lower SES areas for 12 of 15 relatively common types of cancer. In contrast, no such SES-survival associations were found for 12 of 15 cancer types in Toronto. Between-country analysis, which compared cases arising from Toronto and Detroit's low-income areas, revealed a significant Toronto survival advantage for 13 of 15 most prevalent cancers. Other studies demonstrated that such Canadian advantage was maintained even with a conservative comparison of Toronto's poor with Detroit's near poor,² as well as in other Canada-U.S. comparative locales.^{3–5} Furthermore, SES acted as an effect modifier, that is, significant country-by-SES interactions were observed. Canadian survival advantages were observed only among the ecologically defined poor (residents of low-income neighborhoods). The present study aims to advance understanding of the factors associated with such disadvantaged survival among people with cancer in the United States.

Nine of 10 U.S. studies on cancer survival during the past 10 years have found a significant disadvantage with low SES.^{1,3,6} Survival among those of relatively high SES was found to be 49 percent greater than that of their lower status counterparts. A similar SES-cancer survival association, although of attenuated magnitude (13 percent differential), has also been observed in other developed continental European and Nordic countries, as well as Australia.^{7–10} Interestingly, the aggregate SES-cancer survival differential among Canadian cohorts has been found to be only 3 percent.^{1–5,11,12} Health care systems differences, such as the greater representation of universally accessible single-payer systems in Nordic and other European countries, and Canada, may parsimoniously account for the greatly diminished SES-cancer survival associations found in these countries compared with the United States. Studies of race and cancer survival have provided further evidence for an SES-survival association in the United States.^{13–16} Cumulative cancer survival among blacks was found to be approximately 43 percent less than that of whites, but this difference

diminished to only 8 percent in studies that provided any adjustment for socioeconomic factors or health care access.¹⁷

This analytic picture seems straightforward, but its valid policy interpretation is complicated by a number of other known relationships. For example, in the United States, such social factors as SES and race are both highly associated with cancer prognostic and treatment factors,^{18–25} which themselves are highly associated with cancer survival in the United States and other countries.^{26–28} Moreover, the associations of social factors with tumor biology in the United States^{29–32} and the associations of social factors with prognosis and treatment in other countries, including Canada,^{33–36} have all been observed to be extremely small or nonsignificant. Separately, each of these meta-estimates seems to be most consistent with a systemic, rather than an individual biological-behavioral, account. This study aims to measure the relative weight of all these factors—social, biological, standard prognostic, and therapeutic—in predicting cancer survival among a well-defined U.S. population.

Method

Cancer cases from the population of metropolitan Detroit, Michigan (3.9 million in 1990; Wayne, Oakland, and Macomb counties) were ascertained by the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) program.^{37–39} Primary, malignant, adult (25 years of age or older), microscopically confirmed cases among the most common cancer sites with relatively good prognoses (five-year survival 50 percent or greater for any SES group) were included in the analysis: breast (ICD-9 code 174), prostate (185), colon (153), rectum (154), bladder (188), kidney (189), corpus uteri (182), cervix uteri (180), and oral (141–9).⁴⁰ These cancers, which account for 57 percent of all incident cases in metropolitan Detroit, may reasonably be expected to be most affected by health systems access and treatment differences. The study cohort was constrained by the following: 1984 was the first year in which SEER coded nearly all cases by residence, and the date of last follow-up was December 31, 1995. The cohort for five-year survival analysis was based on 58,023 incident cases between 1984 and 1990.

Cancer cases were joined by census tracts at the time of their diagnosis to socioeconomic data collected by the 1990 population census. The federally established, consumer price index-based and household size-adjusted, poverty criterion was then used to divide the cohort into relative socioeconomic areas:³⁷ high-income (2 percent of households below poverty, median annual household income of \$51,500) and middle-income (7 percent poor, median income of \$35,700) versus low-income (36 percent poor, median income of \$17,800) areas. All of the other study variables were collected by SEER and assessed at the level of individuals: race (white or black), stage (localized or regional/distant), cancer-directed surgery and radiation therapy (none or some), vital status (alive or dead), and underlying cause of death. Other racial strata were excluded because there was insufficient statistical power to assess effects among them adequately. Multivariate analyses of five-year cancer survival were accomplished with proportion hazards regression models that considered deaths from causes other than cancer as censored observations at the time of death.^{41,42} Of the cases dead at follow-up (47 percent), 78 percent died as a direct result of cancer. The model's proportional hazards assumption appears to have been met as no study

factors produced a significant differential survival effect (no factor-by-year of diagnosis interaction was significant).

Results

A series of increasingly complex proportional hazards models are displayed in Table 1. The simplest model, which regressed cancer survival only on race, found them to be highly associated among both women and men (respective black hazard ratios [HRs] of 1.65 and 1.69; Model 1). Next, models that regressed cancer survival only on social characteristics found that SES was also highly associated with five-year survival among women and men (respective low-income HRs of 1.62 and 1.49; Model 2). After income status adjustment, race made an additional contribution to the risk of dying among women (HR = 1.46), but not men. Next, a model built on prognostic and treatment factors along with SES and race, which essentially sorted for the most treatable cancers in its first step, found extraordinarily large effects of stage among both women and men (HRs of 12.23 and 8.63; Model 3). It then entered the combined treatment factors of surgery and radiation therapy among women and men (HRs of 3.16 and 1.79). The nonreceipt of stage-appropriate cancer-directed treatments was associated with respective two- to threefold greater risks of death within five years among male and female cancer patients.

Discussion

This study found that SES, race, stage of disease at diagnosis, and the experience of any surgical or radiation therapy were all significantly predictive of five-year survival among a cohort of patients with relatively screenable and treatable types of cancers. Across multivariate models, adjusted hazard ratios—which are interpretable as the relative risk of dying from cancer among the poor (ranged from 1.28 to 1.62), black women (1.31 to 1.46), those with more advanced disease (8.63 to 12.23), and those who did not receive cancer-directed treatments (1.79 to 3.16)—were not only statistically significant but also practically indicative of quite large effects. Black people were also observed to be nearly five times more likely to live in relatively poor neighborhoods where advanced disease at diagnosis and its nontreatment are more prevalent. These findings are consistent with the multiple disadvantaged statuses of people of color on such risk indicators as duration and severity of impoverishment, and being under- or uninsured. They are also consistent with the possibility of residual confounding resultant from only rather gross ecological adjustment for SES. It is well known that within many poor U.S. strata, black people are much poorer, on average, than are white people. Within this study's low-income areas, for example, the typical African American household had an annual income of \$15,100 in 1990, while the typical white household had an income of \$23,300. It certainly seems probable that the observed residual race-survival hazard is more likely a function of unadjusted socioeconomic and other contextual factors, rather than an effect of race per se. This study's findings seem to implicate health care systemic factors such as access to primary and cancer care; therefore, policy interventions that provide for more equitable initial access to the health care system, as well as similar access to the most appropriate treatments once diagnosed, may be expected to have large beneficial public health effects.

Methodological issues

Using dichotomous stage and treatment variables, which were conveniently available through the SEER program, as proxies for more complex ones (access and treatment protocols), we observed strong associations with cancer survival. Future research in this field ought to build more complex models that can provide more of an explanation for health and health care inequity problems. For example, SEER has begun making available more detailed extent of disease information, including tumor size, extension of tumor, and lymph node involvement. Analyses of post-1987 cohorts will be able to incorporate them. Also, although this study was able to assess gatekeeping treatment factors, it lacked surgical and radiation protocol detail, as well as information on chemo and adjuvant therapies, which would go a long way toward facilitating the connection between clinical practice and health care policy development in the United States.

The income variable used in this study was ecological. Its analytic goal, however, was merely to assign individuals to one of three broad SES classifications. Any information bias that may intrude is far less potent when aggregating cancer cases into tertiles, as this study did, than when such ecological measures are analytically employed as direct proxies for each individual's SES.^{43–46} Furthermore, the magnitude of such error compares favorably with that encountered in related epidemiological domains and is likely to be non-differential.^{47,48} The ecological fallacy notwithstanding, we believe that it is important simply to know that in the United States where people with cancer live is closely associated with how long they live. In other words, place itself becomes an important determinant of cancer survival.⁴⁹ This study's contextual inferences are thus most relevant to understanding systemic, community-level phenomena.^{50,51} Insurance status is one such factor that fits with this study's findings.

Possible alternative explanations

A number of other factors possibly could explain cancer survival disadvantages among people who live in relatively poor neighborhoods. For example, cultural hypotheses related to differences between class or ethnic groups on cancer-preventive behaviors and rates of cancer screening participation have been developed but remain largely untested. In fact, it is actually the level of achieved education and knowledge, rather than any culture-specific attitude or belief differences, that accounts for much of the observed differences on cancer screening.^{52–55} It is also possible that so-called lead time bias could explain the observed SES-cancer survival gradients. It could be that cancers generally are being detected earlier among those of higher SES, so that while observed survival time has been artifactually extended among them because their diagnoses have been moved forward, their real survival times are actually unaffected. We feel confident in ruling out lead time bias as a potent explanation for the following reasons: (1) adjusting for lead time, cancer stage has consistently been found to be associated with survival;^{26,56–58} (2) adjusting for lead time and stage, other delays in diagnostic and treatment processes do not seem to be significantly associated with survival;⁵⁸ (3) this study's findings were homogeneous across cancers with diverse natural histories including their preclinical phase lengths; and (4) this study found treatment to be associated with survival after stage differences were accounted for. Finally, lifestyle factors that have been observed to be strongly associated with the occurrence of

some cancers are only weakly associated with cancer survival, if at all.^{59–62} It is unlikely that these personal factors could account for the consistently observed SES-survival gradients. On the other hand, 8 of every 10 households in this study's low-income neighborhoods were categorically defined as poor or near poor (up to 200 percent of the poverty threshold),³⁷ and it is precisely such groups of people who are at the greatest risk of being uninsured or underinsured.¹⁸ It seems that the elucidation of possible alternative explanations tends to further support, rather than refute, the plausibility of the health insurance explanation for this study's findings.

The unifying construct of health insurance status

Consistent with the health systems hypothesis, health insurance status in the United States' multitiered system is associated closely with SES and race/ethnicity,^{63–65} which themselves are associated closely with the use of cancer screens and physician and hospital services. Insurance status in the United States is also known to be associated with cancer stage, investigations and treatments, and with survival.^{19,66–69} Contrary to findings among U.S. samples, SES has generally not been found to be associated with the use of services in Canada,^{70–72} and the SES-cancer screen association among Americans is two-thirds larger than the Canadian one.⁷³ Some delay to treatment problems have been described among Canadian samples, but they have not accounted for SES in any way.^{74–76} Such problems seem to be associated with provincial or regional cancer care service endowments, rather than with personal income or other such individual factors.

Perhaps the best evidence that it is predominantly systemic factors that predict cancer survival is the consistent secular trend of a 10 to 25 percent improvement in cancer survival during the past two decades across diverse North American and European countries. As increasingly effective treatments have been made available, more cancer patients have survived for longer periods of time.^{77–79} During the mere five years when adjuvant systemic therapy was made available in British Columbia, breast cancer survival increased 15 percent.⁷⁹ In the same connection, many (37 percent, breast) and, in some cases, the majority of cancer patients in the United States (colon, rectum) do not receive the best available treatments.^{80,81} This research, and that of many others, very strongly suggests that in the United States, access to such best treatments is associated closely with SES, race, and ultimately with insurance status. Thus, it also strongly suggests that movement to a more universally accessible health care system such as Canada's, though not a panacea, certainly would result in more equitable enjoyment of health care resources and consequently more favorable health outcomes among all Americans.

Acknowledgments

This study was supported in part by a career investigator award to its principal investigator that is jointly funded by the Canadian Institutes of Health Research, the Social Sciences and Humanities Research Council of Canada (SSHRC), and Health Canada. An internal grant from the University of Windsor that was funded by SSHRC also supported this research. The authors gratefully acknowledge the technical assistance provided by Robyn J. Nease, MA, statistical consultant, Computing Services, University of Windsor.

References

1. Gorey KM, Holowaty EJ, Fehringer G, et al. An international comparison of cancer survival: Toronto, Ontario and Detroit, Michigan metropolitan areas. *Am J Public Health*. 1997 Jul; 87(7): 1156–63. [PubMed: 9240106]
2. Gorey KM, Holowaty EJ, Laukkanen E, et al. An international comparison of cancer survival: Advantage of Canada's poor over the near poor of the United States. *Can J Public Health*. 1998 Mar-Apr;89(2):102–4. [PubMed: 9583250]
3. Gorey KM, Holowaty EJ, Fehringer G, et al. An international comparison of cancer survival: Toronto, Ontario and Honolulu, Hawaii metropolitan areas. *Am J Public Health*. 2000 Dec; 90(12): 1866–72. [PubMed: 11111258]
4. Gorey KM, Holowaty EJ, Fehringer G, et al. An international comparison of cancer survival: Toronto, Ontario and three relatively resourceful United States metropolitan areas. *J Public Health Med*. 2000 Sep; 22(3):343–48. [PubMed: 11077908]
5. Gorey KM, Kliever E, Holowaty EJ, et al. An international comparison of breast cancer survival: Winnipeg, Manitoba and Des Moines, Iowa metropolitan areas. *Ann Epidemiol*. 2003 Jan; 13(1): 32–41. [PubMed: 12547483]
6. Polednak AP. Survival of breast cancer patients in Connecticut in relation to socioeconomic and health care access indicators. *J Urban Health*. 2002 Jun; 79(2):211–18. [PubMed: 12023496]
7. Hole HJ, McArdle CS. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer. *Br J Surg*. 2002 May; 89(5):586–90. [PubMed: 11972548]
8. Coleman MP, Babb P, Sloggett A, et al. Socioeconomic inequalities in cancer survival in England and Wales. *Cancer*. 2001 Jan 1; 91(1 Suppl):208–16. [PubMed: 11148581]
9. Edwards DM, Jones J. Incidence of and survival from upper aerodigestive tract cancers in the U.K.: The influence of deprivation. *Eur J Cancer*. 1999 Jun; 35(6):968–72. [PubMed: 10533480]
10. Taylor R. Breast cancer five-year survival, by New South Wales regions, 1980 to 1991. *Aust N Z J Public Health*. 1997 Apr; 21(2):206–10. [PubMed: 9161079]
11. Boyd C, Zhang-Salomons JY, Groome PA, et al. Associations between community income and cancer survival in Ontario, Canada, and the United States. *J Clin Oncol*. 1999 Jul; 17(7):2244–55. [PubMed: 10561282]
12. Stavraky KM, Skillings JR, Stitt LW, et al. The effect of socioeconomic status on the long-term outcome of cancer. *J Clin Epidemiol*. 1996 Oct; 49(10):1155–60. [PubMed: 8826996]
13. Blackstock AW, Herndon JE II, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: Report from the cancer and leukemia group B. *J Natl Cancer Inst*. 2002 Feb 20; 94(4):284–90. [PubMed: 11854390]
14. Moore RJ, Doherty DA, Do KA, et al. Racial disparity in survival of patients with squamous cell carcinoma of the oral cavity and pharynx. *Ethn Health*. 2001 Aug-Nov;6(3–4):165–77. [PubMed: 11696928]
15. Joslyn SA, West MM. Racial differences in breast carcinoma survival. *Cancer*. 2000 Jan 1; 88(1): 114–23. [PubMed: 10618613]
16. Robbins AS, Whittemore AS, Thom DH. Differences in socioeconomic status and survival among white and black men with prostate cancer. *Am J Epidemiol*. 2000 Feb 15; 151(4):409–16. [PubMed: 10695600]
17. Gorey KM. Canada-United States comparative cancer care: Systematic review-generated hypotheses and methodological direction for future research. In: Goel, V., editor. *Canada/U.S. comparisons of health services: Methodological issues and interpretations*; Symposium conducted at the North American Congress of Epidemiology; Toronto. June 14–16, 2001;
18. Gorey KM. What is wrong with the U.S. health care system? It does not effectively exist for one of every five Americans. *Milbank Q*. 1999; 77(3):401–7. [PubMed: 10526551]
19. Hewitt M, Devesa S, Breen N. Papanicolaou test use among reproductive-age women at high risk for cervical cancer: Analyses of the 1995 National Survey of Family Growth. *Am J Public Health*. 2002 Apr; 92(4):666–69. [PubMed: 11919069]
20. Merkin SS, Stevenson L, Powe N. Geographic socioeconomic status, race, and advanced-stage breast cancer in New York City. *Am J Public Health*. 2002 Jan; 92(1):64–70. [PubMed: 11772763]

21. Miller BA, Hankey BF, Thomas TL. Impact of sociodemographic factors, hormone receptor status, and tumor grade on ethnic differences in tumor stage and size for breast cancer in US women. *Am J Epidemiol*. 2002 Mar 15; 155(6):534–45. [PubMed: 11882527]
22. Earle CC, Neumann PJ, Gelber RD, et al. Impact of referral patterns on the use of chemotherapy for lung cancer. *J Clin Oncol*. 2002 Apr 1; 20(7):1786–92. [PubMed: 11919235]
23. VanEenwyk J, Campo JS, Ossiander EM. Socioeconomic and demographic disparities in treatment of carcinoma of the colon and rectum. *Cancer*. 2002 Jul 1; 95(1):39–46. [PubMed: 12115315]
24. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. *Urology*. 2000 May; 55(5):730–35. [PubMed: 10792091]
25. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer. *N Engl J Med*. 1999 Oct 14; 341(16):1198–205. [PubMed: 10519898]
26. Preston DM, Bauer JJ, Connelly RR, et al. Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988–1995. *Urology*. 1999 Jan; 53(1):131–38. [PubMed: 9886602]
27. Kallakury BV, Sheehan CE, Ambros RA, et al. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. *Cancer*. 1997 Aug 15; 80(4):753–63. [PubMed: 9264360]
28. Lyman GH, Kuderer NM, Lyman SL, et al. Importance of race in breast cancer survival. *Ann Surg Oncol*. 1997 Jan; 4(1):80–87. [PubMed: 8985521]
29. Barroso U Jr, Oskanian P, Tefilli MV, et al. Population-based study of pelvic lymph node positivity in clinically localized prostate cancer: A study comparing African Americans and whites. *Urology*. 1999 Jan; 53(1):187–91. [PubMed: 9886610]
30. Witte MN, Kattan MW, Albani J, et al. Race is not an independent predictor of positive surgical margins after radical prostatectomy. *Urology*. 1999 Nov; 54(5):869–74. [PubMed: 10565749]
31. Chen VW, Fenoglio-Preiser CM, Wu XC, et al. Aggressiveness of colon carcinoma in blacks and whites. National Cancer Institute Black/White Cancer Survival Study Group. *Cancer Epidemiol Biomarkers Prev*. 1997 Dec; 6(12):1087–93. [PubMed: 9419408]
32. Krieger N, van den Eeden SK, Zava D, et al. Race/ethnicity, social class, and prevalence of breast cancer prognostic biomarkers: A study of white, black, and Asian women in the San Francisco bay area. *Ethn Dis*. 1997 Spring-Summer; 7(2):137–49. [PubMed: 9386954]
33. Goel V, Olivotto I, Hislop TG, et al. Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group. *CMAJ*. 1997 Jan 1; 156(1):25–35. [PubMed: 9006561]
34. Mustard CA, Derksen S, Berthelot J, Wolfson M, Roos LL. Age-specific education and income gradients in morbidity and mortality in a Canadian province. *Soc Sci Med*. 1997 Aug; 45(3):383–97. [PubMed: 9232733]
35. Sawka C, Olivotto I, Coldman A, Goel V, et al. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. *Br J Cancer*. 1997; 75(10):1534–42. [PubMed: 9166950]
36. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: A study of 3786 patients in the west of Scotland. *BMJ*. 1996 Jan 20; 312(7024):145–48. [PubMed: 8563532]
37. U.S. Bureau of the Census. 1990: Summary tape file 3 on CD-ROM (Michigan). Washington, DC: Data User Services Division; 1992. Census of population and housing.
38. U.S. Department of Health and Human Services. National Institutes of Health. Surveillance, epidemiology, and end results (SEER) program: Public use CD-ROM (1973–93). Washington, DC: National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch; 1996.
39. U.S. Department of Health and Human Services. National Institutes of Health. Surveillance, epidemiology, and end results (SEER) program: Public use CD-ROM (1973–95). Washington, DC: National Cancer Institute, DCPC, Surveillance Program, Cancer Statistics Branch; 1997.
40. Percy, C., Van Holten, V., Muir, C. International classification of diseases for oncology. 2. Geneva: World Health Organization; 1990.
41. Cox DR. Regression models and life tables (with discussion). *J R Stat Soc B*. 1972; 34:187–220.
42. Dixon, WJ., editor. BMDP statistical software manual (Vol. 2, to accompany release 7). Berkeley: University of California Press; 1992.

43. Greenwald HP, Polissar NL, Borgatta EF, et al. Detecting survival effects of socioeconomic status: Problems in the use of aggregate measures. *J Clin Epidemiol*. 1994 Aug; 47(8):903–9. [PubMed: 7730894]
44. Cherkin DC, Grothaus L, Wagner EH. Is magnitude of co-payment effect related to income? Using census data for health services research. *Soc Sci Med*. 1992 Jan; 34(1):33–41. [PubMed: 1738854]
45. Krieger N. Overcoming the absence of socioeconomic data in medical records: Validation and application of a census-based methodology. *Am J Public Health*. 1992 May; 82(5):703–10. [PubMed: 1566949]
46. Krieger N. Women and social class: A methodological study comparing individuals, households, and census measures as predictors of black/ white differences in reproductive history. *J Epidemiol Community Health*. 1991 Mar; 45(1):35–42. [PubMed: 2045742]
47. Brenner H, Savitz DA, Jockel K-H, Greenland S. Effects of nondifferential exposure misclassification in ecological studies. *Am J Epidemiol*. 1992 Jan 1; 135(1):85–95. [PubMed: 1736664]
48. Flegal KM, Brownie C, Haas JD. The effects of exposure misclassification on estimates of relative risk. *Am J Epidemiol*. 1986 Apr; 123(4):736–51. [PubMed: 3953551]
49. Macintyre S, Ellaway A, Cummins S. Place effects on health: How can we conceptualise, operationalise and measure them? *Soc Sci Med*. 2002 Jul; 55(1):125–39. [PubMed: 12137182]
50. Gorey KM, Vena JE. The association of near poverty status with cancer incidence among black and white adults. *J Community Health*. 1995 Aug; 20(4):359–66. [PubMed: 7593741]
51. Schwartz S. The fallacy of the ecological fallacy: The potential misuse of a concept and the consequences. *Am J Public Health*. 1994 May; 84(5):819–24. [PubMed: 8179055]
52. Henderson LM, Schenck AP. Identifying and characterizing one-time and never users of mammography screening services among Medicare eligible women. *Prev Med*. 2001 Jun; 32(6): 529–33. [PubMed: 11394957]
53. Wu ZH, Black SA, Markides KS. Prevalence and associated factors of cancer screening: Why are so many older Mexican American women never screened? *Prev Med*. 2001 Oct; 33(4):268–73. [PubMed: 11570830]
54. McKee MD, Lurio J, Marantz P, et al. Barriers to follow-up of abnormal Papanicolocou smears in an urban community health center. *Arch Fam Med*. 1999 Mar-Apr; 8(2):129–34. [PubMed: 10101983]
55. O'Malley AS, Kerner J, Johnson AE, et al. Acculturation and breast cancer screening among Hispanic women in New York City. *Am J Public Health*. 1999 Feb; 89(2):219–27. [PubMed: 9949753]
56. Merrill RM, Henson DE, Ries LA. Conditional survival estimates in 34,963 patients with invasive carcinoma of the colon. *Dis Colon Rectum*. 1998 Sep; 41(9):1097–106. [PubMed: 9749492]
57. Franzini L, Williams AF, Franklin J, et al. Effects of race and socioeconomic status of 1,332 black, Hispanic, and white women with breast cancer. *Ann Surg Oncol*. 1997 Mar; 4(2):111–18. [PubMed: 9084846]
58. Richards MA, Westcombe AM, Love SB, et al. Influence of delay on survival in patients with breast cancer: A systematic review. *Lancet*. 1999 Apr 3; 353(9159):1119–26. [PubMed: 10209974]
59. de Graeff A, de Leeuw JR, Ros WJ, et al. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. *Eur J Cancer*. 2001 Feb; 37(3):332–39. [PubMed: 11239754]
60. Maunsell E, Brisson J, Mondor M, et al. Stressful life events and survival after breast cancer. *Psychosom Med*. 2001 Mar-Apr; 63(2):306–15. [PubMed: 11292280]
61. Holmes MD, Stampfer MJ, Colditz GA, et al. Dietary factors and the survival of women with breast carcinoma. *Cancer*. 1999 Sep 1; 86(5):826–35. [PubMed: 10463982]
62. Meyer F, Bairati I, Shadmani R, et al. Dietary fat and prostate cancer survival. *Cancer Causes Control*. 1999 Aug; 10(4):245–51. [PubMed: 10482482]
63. Granados G, Puwula J, Berman N, et al. Health care for Latino children: Impact of child and parental birthplace on insurance status and access to health services. *Am J Public Health*. 2001 Nov; 91(11):1806–7. [PubMed: 11684608]

64. Seccombe K, Amey C. Playing by the rules and losing: Health insurance and the working poor. *J Health Soc Behav.* 1995 Jun; 36(2):168–81. [PubMed: 9113141]
65. Blendon RJ, Aiken LH, Freeman HE, et al. Access to medical care for black and white Americans: A matter of continuing concern. *JAMA.* 1989 Jan 13; 261(2):278–81. [PubMed: 2909026]
66. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. *J Natl Cancer Inst.* 2002 Apr 3; 94(7):490–96. [PubMed: 11929949]
67. Roetzheim RG, Pal N, Gonzalez EC, et al. Effects of health insurance and race on colorectal cancer treatments and outcomes. *Am J Public Health.* 2000 Nov; 90(11):1746–54. [PubMed: 11076244]
68. Lee-Feldstein A, Feldstein PJ, Buchmueller T, et al. The relationship of HMOs, health insurance, and delivery systems to breast cancer outcomes. *Med Care.* 2000 Jul; 38(7):705–18. [PubMed: 10901354]
69. Katz SJ, Zemencuk JK, Hofer TP. Breast cancer screening in the United States and Canada, 1994:Socioeconomic gradients persist. *Am J Public Health.* 2000 May; 90(5):799–803. [PubMed: 10800435]
70. Dunlop S, Coyte PC, McIsaac W. Socio-economic status and the utilisation of physicians' services: Results from the Canadian National Population Health Survey. *Soc Sci Med.* 2000 Jul; 51(1):123–33. [PubMed: 10817475]
71. McIsaac W, Goel V, Naylor D. Socioeconomic status and visits to physician by adults in Ontario, Canada. *J Health Serv Res Policy.* 1997 Apr; 2(2):94–102. [PubMed: 10180371]
72. Katz SJ, Hofer TP, Manning WG. Hospital utilization in Ontario and the United States: The impact of socioeconomic status and health status. *Can J Public Health.* 1996 Jul-Aug; 87(4):253–56. [PubMed: 8870304]
73. Katz SJ, Hofer TP. Socioeconomic disparities in preventive care persist despite universal coverage: Breast and cervical cancer screening in Ontario and the United States. *JAMA.* 1994 Aug 17; 272(7):530–34. [PubMed: 8046807]
74. Mackillop WJ, Groome PA, Zhang-Solomons J, et al. Does a centralized radiotherapy system provide adequate access to care? *J Clin Oncol.* 1997 Mar; 15(3):1261–71. [PubMed: 9060571]
75. Mackillop WJ, Fu H, Quirt CF, et al. *Int J Radiat Oncol Biol Phys.* 1994 Aug 30; 30(1):221–28. [PubMed: 8083117]
76. Katz SJ, Hislop TG, Thomas DB, et al. Delay from symptom to diagnosis and treatment of breast cancer in Washington State and British Columbia. *Med Care.* 1993 Mar; 31(3):264–68. [PubMed: 8450682]
77. Mettlin C. Changes in patterns of prostate cancer care in the United States: Results of the American College of Surgeons commission on cancer studies, 1974–1993. *Prostate.* 1997 Aug 1; 32(3):221–26. [PubMed: 9254902]
78. van Spronsen DJ, Dijkema IM, Vrints LW, et al. Improved survival of Hodgkin's patients in south-east Netherlands since 1972. *Eur J Cancer.* 1997 Mar; 33(3):436–41. [PubMed: 9155529]
79. Olivetto IA, Bajdik CD, Plenderleith IH, et al. Adjuvant systemic therapy and survival after breast cancer. *N Engl J Med.* 1994 Mar 24; 330(12):805–10. [PubMed: 8114832]
80. Breen N, Wesley MN, Merrill RM, et al. The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. *Ethn Dis.* 1999 Winter; 9(1):111–25. [PubMed: 10355480]
81. U.S. General Accounting Office. Briefing report to the chairman. Subcommittee on Health and the Environment, Committee on Energy and Commerce, House of Representatives; Gathersburg, MD: 1988. Cancer treatment 1975–85: The use of breakthrough treatments for seven types of cancer.

TABLE 1

THE ASSOCIATION OF SOCIAL, PROGNOSTIC, AND TREATMENT FACTORS WITH FIVE-YEAR
CANCER SURVIVAL: COX PROPORTIONAL HAZARDS MODELS

MODEL AND FACTOR (RISK GROUP)	SELECTED REGRESSION MODEL STATISTICS ^a			
	WOMEN (<i>n</i> = 31,855) ^b		MEN (<i>n</i> = 26,168) ^b	
	HR	(95 PERCENT CI) ^c	HR	(95 PERCENT CI)
Model 1				
Race	1.65	(1.54, 1.77)	1.69	(1.55, 1.84)
Model 2				
Income areas	1.62	(1.46, 1.79)	1.49	(1.32, 1.67)
Race	1.46	(1.30, 1.63)	1.13	(0.99, 1.29)
Model 3				
Stage	12.23	(9.45, 15.85)	8.63	(6.95, 10.72)
Cancer-directed treatment	3.16	(2.59, 3.86)	1.79	(1.40, 2.29)
Income areas	1.38	(1.22, 1.57)	1.28	(1.10, 1.48)
Race	1.31	(1.16, 1.49)	1.00	(0.86, 1.16)

Note: Predictor variables were added to models in life space chronological order. Demographic and social characteristics that necessarily precede cancer diagnosis were entered first (age, race, and income area). Next, a factor assessed at diagnosis (stage) was added. And finally, cancer treatment factors (surgery and radiation therapy) were entered. Dummy variables for specific cancer sites did not enter any models after social, prognostic, and treatment factors were accounted for. Therefore, aggregate survival estimates among cancers of relatively good prognoses are this study's central focus.

^a All adjusted for age (25–44, 45–54, 55–64, 65–74, 75 years or older) and other factors in the model.

^b Number of cases with valid data on all factors. Among the six regression models, no analytic strata among women or men, respectively, had fewer than 400 or 300 cases.

^c HR = hazard ratio and 95 percent CI = 95 percent confidence interval. Variables are coded so that a hazard ratio greater than 1.00 is indicative of hypothesis support.